Symbols / PLSE
PLSE Chart
About
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 1.29B |
| Enterprise Value | 1.22B | Income | -72.78M | Sales | 350.00K |
| Book/sh | 1.19 | Cash/sh | 1.19 | Dividend Yield | — |
| Payout | 0.00% | Employees | 116 | IPO | — |
| P/E | — | Forward P/E | -22.16 | PEG | — |
| P/S | 3689.46 | P/B | 16.03 | P/C | — |
| EV/EBITDA | -16.05 | EV/Sales | 3479.74 | Quick Ratio | 10.22 |
| Current Ratio | 10.53 | Debt/Eq | 9.34 | LT Debt/Eq | — |
| EPS (ttm) | -1.14 | EPS next Y | -0.86 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -42.37% |
| ROE | -74.45% | ROIC | — | Gross Margin | -54.00% |
| Oper. Margin | -69.14% | Profit Margin | 0.00% | Shs Outstand | 67.77M |
| Shs Float | 17.79M | Short Float | 14.74% | Short Ratio | 15.55 |
| Short Interest | — | 52W High | 26.30 | 52W Low | 12.56 |
| Beta | 1.80 | Avg Volume | 293.04K | Volume | 45.70K |
| Target Price | $30.00 | Recom | Strong_buy | Prev Close | $18.99 |
| Price | $19.05 | Change | 0.34% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$30.00
Mean price target
2. Current target
$19.06
Latest analyst target
3. DCF / Fair value
$-7.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$19.06
Low
$30.00
High
$30.00
Mean
$30.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-07-07 | init | Oppenheimer | — → Outperform | $22 |
| 2022-09-21 | down | Maxim Group | Buy → Hold | — |
| 2022-05-13 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2022-04-01 | main | Stephens & Co. | — → Overweight | $12 |
| 2022-04-01 | main | HC Wainwright & Co. | — → Buy | $9 |
| 2022-02-10 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2021-11-16 | main | HC Wainwright & Co. | — → Buy | $43 |
| 2021-07-27 | init | Stephens & Co. | — → Overweight | $28 |
| 2021-03-11 | init | Maxim Group | — → Buy | $40 |
| 2021-01-26 | main | HC Wainwright & Co. | — → Buy | $40 |
| 2020-05-12 | up | HC Wainwright & Co. | Neutral → Buy | $16 |
| 2020-02-14 | down | HC Wainwright & Co. | Buy → Neutral | $6 |
| 2019-02-25 | init | HC Wainwright & Co. | — → Buy | — |
- New hires at Pulse Biosciences get 19,000 stock options - Stock Titan Fri, 20 Feb 2026 21
- Pulse Biosciences stock slips despite Q4 beat (PLSE:NASDAQ) - Seeking Alpha Fri, 20 Feb 2026 15
- Pulse Biosciences CCO Danahy sells $118k in PLSE stock - Investing.com ue, 24 Feb 2026 02
- Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance hu, 19 Feb 2026 22
- Pulse Biosciences Inc (PLSE) Shares Gap Down to $22.02 on Feb 20 - GuruFocus Fri, 20 Feb 2026 16
- Pulse Biosciences Stock Pre-Market (+5.5%): Searching for a Catalyst - Trefis Sat, 07 Feb 2026 11
- Pulse Biosciences Shares Fall After Q4 Loss Widens as Clinical Spending Rises and Revenue Remains Limited - AlphaStreet News hu, 19 Feb 2026 22
- PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data - Nasdaq Mon, 09 Feb 2026 08
- The Technical Signals Behind (PLSE) That Institutions Follow - Stock Traders Daily hu, 19 Feb 2026 16
- Pulse Biosciences Launches $59.98 Million ATM Equity Program With TD Cowen - TradingView hu, 19 Feb 2026 21
- Pulse Biosciences Establishes New $60 Million ATM Program - TipRanks hu, 19 Feb 2026 21
- Watch Pulse Biosciences’ TD Cowen healthcare webcast live Mar. 4 - Stock Titan Fri, 20 Feb 2026 12
- Heart procedure trial hits 100% success as FDA okays pivotal study - Stock Titan hu, 19 Feb 2026 21
- Oppenheimer raises Pulse Biosciences stock price target to $30 By Investing.com - Investing.com Nigeria Fri, 20 Feb 2026 13
- Pulse Biosciences to detail 2025 results in Feb. 19 investor call - Stock Titan Wed, 04 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5000 | 118200.0 | — | Sale at price 23.64 per share. | DANAHY KEVIN PATRICK | Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 5000 | 7650.0 | — | Conversion of Exercise of derivative security at price 1.53 per share. | DANAHY KEVIN PATRICK | Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 60000 | 1410600.0 | — | Sale at price 23.37 - 23.63 per share. | DANAHY KEVIN PATRICK | Officer | — | 2026-02-17 00:00:00 | D |
| 3 | 60000 | 91800.0 | — | Conversion of Exercise of derivative security at price 1.53 per share. | DANAHY KEVIN PATRICK | Officer | — | 2026-02-17 00:00:00 | D |
| 4 | 60000 | 1403400.0 | — | Sale at price 21.45 - 25.20 per share. | DANAHY KEVIN PATRICK | Officer | — | 2026-02-11 00:00:00 | D |
| 5 | 60000 | 91800.0 | — | Conversion of Exercise of derivative security at price 1.53 per share. | DANAHY KEVIN PATRICK | Officer | — | 2026-02-11 00:00:00 | D |
| 6 | 4600 | 85238.0 | — | Sale at price 18.53 per share. | DANAHY KEVIN PATRICK | Officer | — | 2025-10-02 00:00:00 | D |
| 7 | 4600 | 7038.0 | — | Conversion of Exercise of derivative security at price 1.53 per share. | DANAHY KEVIN PATRICK | Officer | — | 2025-10-02 00:00:00 | D |
| 8 | 20400 | 377192.0 | — | Sale at price 18.48 - 18.49 per share. | DANAHY KEVIN PATRICK | Officer | — | 2025-09-19 00:00:00 | D |
| 9 | 20400 | 31212.0 | — | Conversion of Exercise of derivative security at price 1.53 per share. | DANAHY KEVIN PATRICK | Officer | — | 2025-09-19 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -55.08M | -42.37M | -56.70M | -61.87M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -53.59M | -42.21M | -58.51M | -63.66M |
| ReconciledDepreciation | 1.18M | 1.21M | 1.35M | 1.15M |
| ReconciledCostOfRevenue | 0.00 | 11.94M | 1.97M | |
| EBITDA | -55.08M | -42.37M | -56.70M | -61.87M |
| EBIT | -56.26M | -43.57M | -58.06M | -63.01M |
| NetInterestIncome | 2.67M | 1.36M | -448.00K | -646.00K |
| NormalizedIncome | -53.59M | -42.21M | -58.51M | -63.66M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -53.59M | -42.21M | -58.51M | -63.66M |
| TotalExpenses | 56.26M | 43.57M | 58.76M | 64.43M |
| TotalOperatingIncomeAsReported | -56.26M | -43.57M | -58.06M | -63.01M |
| DilutedAverageShares | 58.40M | 49.74M | 34.51M | 28.44M |
| BasicAverageShares | 58.40M | 49.74M | 34.51M | 28.44M |
| DilutedEPS | -0.92 | -0.85 | -1.69 | -2.24 |
| BasicEPS | -0.92 | -0.85 | -1.69 | -2.24 |
| DilutedNIAvailtoComStockholders | -53.59M | -42.21M | -58.51M | -63.66M |
| NetIncomeCommonStockholders | -53.59M | -42.21M | -58.51M | -63.66M |
| NetIncome | -53.59M | -42.21M | -58.51M | -63.66M |
| NetIncomeIncludingNoncontrollingInterests | -53.59M | -42.21M | -58.51M | -63.66M |
| NetIncomeContinuousOperations | -53.59M | -42.21M | -58.51M | -63.66M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -53.59M | -42.21M | -58.51M | -63.66M |
| NetNonOperatingInterestIncomeExpense | 2.67M | 1.36M | -448.00K | -646.00K |
| TotalOtherFinanceCost | -2.67M | -1.36M | 448.00K | 646.00K |
| OperatingIncome | -56.26M | -43.57M | -58.06M | -63.01M |
| OperatingExpense | 56.26M | 43.57M | 46.81M | 62.46M |
| ResearchAndDevelopment | 32.34M | 27.80M | 20.84M | 28.64M |
| SellingGeneralAndAdministration | 23.92M | 15.78M | 25.97M | 33.82M |
| SellingAndMarketingExpense | 0.00 | 12.02M | 14.75M | |
| GeneralAndAdministrativeExpense | 23.92M | 15.78M | 13.96M | 19.07M |
| OtherGandA | 23.92M | 15.78M | 13.96M | 19.07M |
| GrossProfit | 0.00 | -11.24M | -550.00K | |
| CostOfRevenue | 0.00 | 11.94M | 1.97M | |
| TotalRevenue | 0.00 | 0.00 | 700.00K | 1.42M |
| OperatingRevenue | 0.00 | 0.00 | 700.00K | 1.42M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 65.93M | 56.08M | 37.87M | 30.22M |
| ShareIssued | 65.93M | 56.08M | 37.87M | 30.22M |
| NetDebt | 4.78M | |||
| TotalDebt | 8.90M | 9.14M | 75.96M | 11.25M |
| TangibleBookValue | 110.85M | 39.68M | -7.59M | 29.68M |
| InvestedCapital | 114.86M | 44.36M | 63.67M | 36.13M |
| WorkingCapital | 109.39M | 38.62M | 56.17M | 28.11M |
| NetTangibleAssets | 110.85M | 39.68M | -7.59M | 29.68M |
| CapitalLeaseObligations | 8.90M | 9.14M | 10.04M | 10.81M |
| CommonStockEquity | 114.86M | 44.36M | -2.25M | 35.69M |
| TotalCapitalization | 114.86M | 44.36M | 62.75M | 35.69M |
| TotalEquityGrossMinorityInterest | 114.86M | 44.36M | -2.25M | 35.69M |
| StockholdersEquity | 114.86M | 44.36M | -2.25M | 35.69M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 0.00 | 0.00 | 0.00 |
| RetainedEarnings | -390.50M | -336.92M | -294.70M | -236.20M |
| AdditionalPaidInCapital | 505.30M | 381.22M | 292.42M | 271.86M |
| CapitalStock | 66.00K | 55.00K | 37.00K | 29.00K |
| CommonStock | 66.00K | 55.00K | 37.00K | 29.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 17.60M | 14.79M | 80.12M | 18.56M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.54M | 8.09M | 74.14M | 10.04M |
| LongTermDebtAndCapitalLeaseObligation | 7.54M | 8.09M | 74.14M | 10.04M |
| LongTermCapitalLeaseObligation | 7.54M | 8.09M | 9.14M | 10.04M |
| LongTermDebt | 65.00M | |||
| CurrentLiabilities | 10.05M | 6.71M | 5.98M | 8.52M |
| CurrentDeferredLiabilities | 0.00 | 16.00K | ||
| CurrentDeferredRevenue | 0.00 | 16.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 1.35M | 1.06M | 1.81M | 1.21M |
| CurrentCapitalLeaseObligation | 1.35M | 1.06M | 896.00K | 774.00K |
| CurrentDebt | 917.00K | 436.00K | ||
| OtherCurrentBorrowings | 917.00K | |||
| CurrentNotesPayable | 0.00 | 436.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.79M | 3.20M | 1.38M | 2.93M |
| CurrentProvisions | 80.00K | |||
| PayablesAndAccruedExpenses | 3.90M | 2.45M | 2.79M | 4.36M |
| CurrentAccruedExpenses | 2.23M | 615.00K | 1.22M | 1.46M |
| Payables | 1.67M | 1.84M | 1.57M | 2.90M |
| AccountsPayable | 1.67M | 1.84M | 1.57M | 2.90M |
| TotalAssets | 132.46M | 59.15M | 77.88M | 54.25M |
| TotalNonCurrentAssets | 13.01M | 13.83M | 15.73M | 17.62M |
| OtherNonCurrentAssets | 677.00K | 365.00K | 365.00K | 365.00K |
| GoodwillAndOtherIntangibleAssets | 4.01M | 4.68M | 5.34M | 6.01M |
| OtherIntangibleAssets | 1.22M | 1.89M | 2.55M | 3.22M |
| Goodwill | 2.79M | 2.79M | 2.79M | 2.79M |
| NetPPE | 8.32M | 8.78M | 10.02M | 11.25M |
| AccumulatedDepreciation | -3.97M | -3.48M | -2.95M | -2.40M |
| GrossPPE | 12.29M | 12.26M | 12.98M | 13.64M |
| Leases | 2.52M | 2.52M | 2.52M | 2.52M |
| ConstructionInProgress | 29.00K | 0.00 | 22.00K | 186.00K |
| OtherProperties | 8.51M | 8.50M | 9.18M | 9.80M |
| MachineryFurnitureEquipment | 1.24M | 1.24M | 1.25M | 1.13M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 119.45M | 45.33M | 62.15M | 36.63M |
| OtherCurrentAssets | 1.41M | 963.00K | 1.01M | 2.13M |
| PrepaidAssets | 2.13M | |||
| Inventory | 0.00 | 5.82M | ||
| FinishedGoods | 0.00 | 2.44M | ||
| WorkInProcess | 0.00 | 1.37M | ||
| RawMaterials | 0.00 | 2.01M | ||
| Receivables | 0.00 | 61.00K | ||
| AccountsReceivable | 0.00 | 61.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 118.04M | 44.37M | 61.14M | 28.61M |
| OtherShortTermInvestments | 0.00 | |||
| CashAndCashEquivalents | 118.04M | 44.37M | 61.14M | 28.61M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -36.47M | -33.16M | -47.41M | -54.53M |
| RepaymentOfDebt | -437.00K | -1.53M | ||
| IssuanceOfDebt | 0.00 | 65.00M | 1.94M | |
| IssuanceOfCapitalStock | 59.65M | 0.00 | 14.86M | 56.70M |
| CapitalExpenditure | -125.00K | -121.00K | -401.00K | -437.00K |
| EndCashPosition | 118.04M | 44.37M | 61.14M | 28.61M |
| BeginningCashPosition | 44.37M | 61.14M | 28.61M | 12.46M |
| ChangesInCash | 73.67M | -16.77M | 32.52M | 16.15M |
| FinancingCashFlow | 110.14M | 16.39M | 79.94M | 62.69M |
| CashFlowFromContinuingFinancingActivities | 110.14M | 16.39M | 79.94M | 62.69M |
| NetOtherFinancingCharges | -281.00K | -6.00K | -437.00K | -232.00K |
| ProceedsFromStockOptionExercised | 50.77M | 16.39M | 512.00K | 5.81M |
| NetCommonStockIssuance | 59.65M | 0.00 | 14.86M | 56.70M |
| CommonStockIssuance | 59.65M | 0.00 | 14.86M | 56.70M |
| NetIssuancePaymentsOfDebt | 0.00 | 65.00M | 407.00K | |
| NetShortTermDebtIssuance | 64.56M | -1.53M | ||
| ShortTermDebtPayments | -437.00K | -1.53M | ||
| ShortTermDebtIssuance | 65.00M | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 65.00M | 1.94M | |
| LongTermDebtPayments | -1.53M | |||
| LongTermDebtIssuance | 0.00 | 65.00M | 1.94M | |
| InvestingCashFlow | -125.00K | -121.00K | -401.00K | 7.56M |
| CashFlowFromContinuingInvestingActivities | -125.00K | -121.00K | -401.00K | 7.56M |
| NetInvestmentPurchaseAndSale | 0.00 | 8.00M | ||
| SaleOfInvestment | 0.00 | 8.00M | ||
| PurchaseOfInvestment | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -125.00K | -121.00K | -401.00K | -437.00K |
| PurchaseOfPPE | -125.00K | -121.00K | -401.00K | -437.00K |
| OperatingCashFlow | -36.34M | -33.04M | -47.01M | -54.10M |
| CashFlowFromContinuingOperatingActivities | -36.34M | -33.04M | -47.01M | -54.10M |
| ChangeInWorkingCapital | 2.47M | 768.00K | -3.72M | -6.20M |
| ChangeInOtherWorkingCapital | -16.00K | 16.00K | ||
| ChangeInOtherCurrentLiabilities | -1.08M | -896.00K | -774.00K | -542.00K |
| ChangeInOtherCurrentAssets | 892.00K | 806.00K | 723.00K | 653.00K |
| ChangeInPayablesAndAccruedExpense | 3.01M | 814.00K | -2.18M | 881.00K |
| ChangeInAccruedExpense | 3.21M | 551.00K | -876.00K | -279.00K |
| ChangeInInterestPayable | 0.00 | -668.00K | 918.00K | 658.00K |
| ChangeInPayable | -201.00K | 263.00K | -1.30M | 1.16M |
| ChangeInAccountPayable | -201.00K | 263.00K | -1.30M | 1.16M |
| ChangeInPrepaidAssets | -403.00K | -65.00K | 1.16M | -1.37M |
| ChangeInInventory | 0.00 | -2.65M | -5.82M | |
| ChangeInReceivables | 48.00K | 109.00K | 20.00K | -7.00K |
| ChangesInAccountReceivables | 0.00 | 61.00K | -61.00K | |
| StockBasedCompensation | 13.59M | 7.18M | 5.19M | 14.60M |
| AssetImpairmentCharge | 0.00 | 8.48M | 0.00 | |
| AmortizationOfSecurities | 0.00 | 13.00K | ||
| DepreciationAmortizationDepletion | 1.18M | 1.21M | 1.35M | 1.15M |
| DepreciationAndAmortization | 1.18M | 1.21M | 1.35M | 1.15M |
| AmortizationCashFlow | 666.00K | 665.00K | 665.00K | 666.00K |
| AmortizationOfIntangibles | 666.00K | 665.00K | 665.00K | 666.00K |
| Depreciation | 512.00K | 542.00K | 690.00K | 480.00K |
| OperatingGainsLosses | 6.00K | 13.00K | 185.00K | |
| GainLossOnSaleOfPPE | 6.00K | 13.00K | 185.00K | 0.00 |
| NetIncomeFromContinuingOperations | -53.59M | -42.21M | -58.51M | -63.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PLSE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|